BLENREP Drug Profile
Summary for Tradename: BLENREP
| High Confidence Patents: | 0 |
| Applicants: | 2 |
| BLAs: | 2 |
| Recent Clinical Trials: | See clinical trials for BLENREP |
Recent Clinical Trials for BLENREP
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Chicago | Phase 2 |
| Cristiana Costa Chase, DO | Phase 2 |
| Merck Sharp & Dohme LLC | Phase 1/Phase 2 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for BLENREP Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for BLENREP Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for BLENREP Derived from Patent Text Search
No patents found based on company disclosures
BLENREP Market Dynamics and Financial Trajectory
BLENREP, or belantamab mafodotin, is GSK’s antibody-drug conjugate for relapsed or refractory multiple myeloma. Its commercial trajectory has been defined by an initial accelerated approval, withdrawal from the U.S. market after a failed confirmatory trial, and a potential relaunch based on positive Phase 3 results from DREAMM-7 and DREAMM-8.
GSK’s near-term value depends less on historical sales and more on whether BLENREP can regain U.S. approval in combination regimens and compete against established BCMA-directed therapies, including CAR-T products and bispecific antibodies.
What is BLENREP and how does it work?
BLENREP combines a B-cell maturation antigen, or BCMA, antibody with the cytotoxic payload auristatin F. The drug binds BCMA on malignant plasma cells, is internalized, and releases the payload to induce cell death.
| Attribute | BLENREP profile |
|---|---|
| Active ingredient | Belantamab mafodotin |
| Drug class | BCMA-directed antibody-drug conjugate |
| Developer and marketer | GSK |
| Primary disease | Relapsed or refractory multiple myeloma |
| Administration | Intravenous infusion |
| Initial U.S. approval | Accelerated approval, August 2020 |
| Initial U.S. indication | Adults with relapsed or refractory multiple myeloma after at least four prior therapies |
| Main safety issue | Ocular toxicity, including corneal events and visual impairment |
| Key development program | DREAMM-7 and DREAMM-8 |
| Commercial status | U.S. approval withdrawn; development continues globally |
The drug’s principal differentiation is a conventional intravenous antibody-drug conjugate mechanism that does not require individualized cell manufacturing. That gives BLENREP a potential logistical advantage over CAR-T therapy, although infusion administration and ocular monitoring remain commercial liabilities.
What is the regulatory status of BLENREP?
BLENREP’s regulatory position is divided by jurisdiction.
United States regulatory history
The FDA granted accelerated approval in August 2020 based on overall response data from the DREAMM-2 study. The approval required a confirmatory trial demonstrating clinical benefit.
DREAMM-3 failed to demonstrate the required progression-free survival benefit against pomalidomide plus low-dose dexamethasone. GSK subsequently withdrew BLENREP’s U.S. marketing authorization. The FDA announced withdrawal of the accelerated approval in October 2022.[1]
The withdrawal did not terminate BLENREP development. GSK continued trials evaluating the drug in earlier treatment lines and in combination with bortezomib and dexamethasone or pomalidomide and dexamethasone.
DREAMM-7 and DREAMM-8
GSK reported positive results from both pivotal studies in 2024.
| Trial | Regimen | Comparator | Strategic significance |
|---|---|---|---|
| DREAMM-7 | BLENREP plus bortezomib and dexamethasone | Daratumumab plus bortezomib and dexamethasone | Supports use after at least one prior line |
| DREAMM-8 | BLENREP plus pomalidomide and dexamethasone | Bortezomib plus pomalidomide and dexamethasone | Supports an alternative post-prior-treatment regimen |
GSK reported statistically significant progression-free survival improvements for both studies. The company stated that it planned regulatory submissions beginning in the second half of 2024.[2][3]
The new data address the principal weakness that caused the original U.S. withdrawal: insufficient evidence of comparative clinical benefit. They do not eliminate the ocular toxicity issue, which remains a key label, monitoring, and adoption concern.
European regulatory status
BLENREP’s European authorization was linked to confirmatory evidence. Following the negative DREAMM-3 result, European regulatory authorities did not support continuation of the original conditional authorization. The European commercial opportunity therefore depends on new regulatory review of the DREAMM-7 and DREAMM-8 data rather than on the original approval pathway.[4]
How has BLENREP revenue changed?
BLENREP generated early commercial revenue after its 2020 launch, but sales weakened as physicians and payers responded to ocular toxicity, the need for frequent ophthalmic monitoring, and uncertainty surrounding the failed confirmatory study.
GSK’s annual reports show a sharp decline from the product’s early commercial period. Exact presentation has varied by reporting year and currency, but the direction is clear.
| Period | Financial development | Main driver |
|---|---|---|
| 2020 | Initial launch revenue | Accelerated U.S. approval and early international launches |
| 2021 | Peak or near-peak commercial period | Use in heavily pretreated multiple myeloma |
| 2022 | Decline | DREAMM-3 failure and U.S. withdrawal process |
| 2023 | Further contraction | Loss of U.S. commercial access and reduced physician utilization |
| 2024 onward | Relaunch-dependent | Positive DREAMM-7 and DREAMM-8 data create a new commercial case |
GSK reported BLENREP sales of approximately £80 million in 2022 and approximately £60 million in 2023, with the reduction reflecting the product’s withdrawal from the U.S. market and constrained use in other regions.[5][6] Those sales are small relative to GSK’s group revenue and its leading specialty medicines, including Trelegy, Nucala, Benlysta, and Arexvy.
The product’s prior revenue base is not a reliable ceiling for post-relaunch sales. A successful approval in earlier treatment settings would expand the addressable population materially. The opposite is also true: continued use only in later-line disease would leave BLENREP exposed to more convenient and increasingly effective competing therapies.
What is the commercial opportunity after a potential relaunch?
The potential relaunch is commercially meaningful because DREAMM-7 and DREAMM-8 move BLENREP into treatment settings with larger patient populations and greater treatment duration.
Addressable market expansion
The original U.S. indication targeted patients who had received at least four prior therapies. That population is narrow and heavily pretreated. The DREAMM-7 and DREAMM-8 populations were treated earlier, after at least one prior line in the relevant study designs.
Earlier-line treatment creates four commercial benefits:
- A larger eligible patient pool.
- Longer potential treatment duration.
- Greater physician familiarity before patients receive CAR-T or later-line bispecific therapy.
- More opportunity to position BLENREP as an off-the-shelf BCMA-directed treatment.
BLENREP will compete in a market that includes:
- Darzalex, or daratumumab, from Johnson & Johnson and Genmab.
- Carvykti, or ciltacabtagene autoleucel, from Johnson & Johnson and Legend Biotech.
- Abecma, or idecabtagene vicleucel, from Bristol Myers Squibb and 2seventy bio.
- Tecvayli, or teclistamab, from Johnson & Johnson.
- Elrexfio, or elranatamab, from Pfizer.
- Multiple established proteasome inhibitor, immunomodulatory, and anti-CD38 regimens.
The most direct competitive comparison is not simply another BCMA drug. It is the full treatment pathway. CAR-T therapy offers deep responses but requires cell collection, manufacturing, specialized centers, and patient waiting time. Bispecific antibodies offer off-the-shelf administration but carry infection, cytokine-release syndrome, and immune-effector cell-associated neurotoxicity risks. BLENREP offers a different profile, but ocular monitoring can restrict use.
How does BLENREP compare with competing multiple myeloma therapies?
| Product | Modality | Main commercial advantage | Principal limitation |
|---|---|---|---|
| BLENREP | BCMA antibody-drug conjugate | Off-the-shelf BCMA targeting; outpatient-compatible infusion model | Ocular toxicity and ophthalmic monitoring |
| Carvykti | BCMA CAR-T | Deep and durable responses | Manufacturing time, capacity constraints, cytokine-release syndrome |
| Abecma | BCMA CAR-T | Established cellular therapy platform | Manufacturing and safety burden |
| Tecvayli | BCMA bispecific antibody | Ready-made treatment with strong response activity | Infections, cytokine-release syndrome, ongoing dosing |
| Elrexfio | BCMA bispecific antibody | Subcutaneous administration and off-the-shelf availability | Immune-related toxicities and infection risk |
| Darzalex | CD38 antibody | Broad physician familiarity and large treatment base | Competitive pressure from newer immune therapies |
BLENREP’s commercial argument is strongest where treatment centers value predictable drug supply and avoid the operational burden of cellular therapy. Its argument is weaker where ophthalmic monitoring is difficult or where physicians prioritize the deepest possible response.
What are BLENREP’s main market risks?
Ocular toxicity
Corneal adverse events were the central factor limiting adoption. BLENREP requires ophthalmic examinations and dose modifications based on eye findings. This creates cost, scheduling, and workflow burdens for both patients and treatment centers.
Risk-management requirements can also influence payer policy. A therapy with a lower acquisition cost can lose commercial share if administration and monitoring expenses are materially higher than those of competing products.
Competitive sequencing
BLENREP may be used before or after CAR-T and bispecific therapy. The sequencing question is commercially important because exposure to prior BCMA-directed therapy can affect the performance of later BCMA agents.
If treatment guidelines place BLENREP after other BCMA therapies, its market could remain narrow. If physicians use it before cellular therapy or as an alternative for patients who cannot receive CAR-T, the opportunity would be larger.
Trial-to-label conversion
Positive progression-free survival data do not automatically guarantee broad reimbursement. Regulators and payers will assess overall survival, safety, ocular-risk management, comparator relevance, and the durability of benefit.
Manufacturing and supply
BLENREP is manufactured as a complex antibody-drug conjugate. Its supply chain is less individualized than CAR-T manufacturing, but it still requires controlled antibody production, conjugation, analytical release testing, and commercial-scale sterile drug production.
GSK’s manufacturing platform is a relative strength because the company has global biologics capabilities. The main risk is commercial, not simply technical: manufacturing capacity must be matched to a market that was previously withdrawn in the United States.
What patent and exclusivity protections cover BLENREP?
BLENREP’s intellectual-property position is built from several layers:
- The belantamab antibody.
- The antibody-drug conjugate structure.
- Linker and auristatin payload chemistry.
- Methods of treating multiple myeloma.
- Combination regimens.
- Manufacturing and formulation processes.
Unlike small-molecule products, biologic exclusivity does not depend only on one compound patent. The commercial protection period can reflect a combination of composition, conjugate, formulation, manufacturing, and method-of-use rights.
The U.S. reference-product exclusivity period for a biologic is 12 years from first licensure under the Biologics Price Competition and Innovation Act. BLENREP’s August 2020 approval would place the 12-year reference-product exclusivity horizon in 2032, subject to statutory adjustments and the specific reference-product designation.[7]
The biologic pathway does not use the same Orange Book patent-listing framework that applies to conventional small-molecule drugs. BLENREP therefore should be analyzed through FDA biologics records, GSK patent families, regulatory exclusivity, and potential biosimilar litigation rather than through a conventional Orange Book review.
Biosimilar risk
A biosimilar competitor cannot enter solely because a patent expires. It must obtain FDA approval through the abbreviated biologics pathway and demonstrate biosimilarity or interchangeability where applicable.
The most important timing variables are:
- FDA reference-product exclusivity.
- Patent expiry and patent-term adjustment.
- Pediatric exclusivity, if granted.
- Regulatory exclusivity in Europe and other markets.
- Patent litigation under the BPCIA.
- The commercial difficulty of developing and manufacturing the antibody-drug conjugate.
BLENREP’s antibody-drug conjugate structure may create a higher technical barrier than a conventional naked antibody. The barrier is not absolute. A biosimilar developer would need to match the antibody, linker-payload relationship, drug-antibody ratio distribution, impurity profile, potency, and clinical performance.
What licensing deals support BLENREP?
BLENREP originated from the antibody-drug conjugate platform associated with ADC Therapeutics’ predecessor technology and related antibody-drug conjugate development rights. GSK has controlled the clinical development and commercialization program.
The strategic value of the product therefore includes more than BLENREP revenue. Successful relaunch would validate GSK’s ability to commercialize an antibody-drug conjugate in a competitive hematology market. A failed relaunch would reduce the economic value of the related development and manufacturing infrastructure.
What litigation and settlement issues affect BLENREP?
The main legal event has been regulatory withdrawal rather than a major public generic or biosimilar challenge.
As of mid-2024:
- The original U.S. accelerated approval had been withdrawn.
- No major publicly disclosed U.S. biosimilar launch challenge had altered the product’s market.
- Future litigation risk would likely arise from patent challenges accompanying a biosimilar application.
- Method-of-use and combination patents could become important if BLENREP receives new approvals based on DREAMM-7 or DREAMM-8.
- Settlement terms would be material if a biosimilar applicant challenges GSK’s patent estate before the end of biologic exclusivity.
What are the likely generic and biosimilar launch scenarios?
BLENREP does not face a conventional generic launch. The relevant risk is biosimilar or follow-on antibody-drug-conjugate entry.
| Scenario | Commercial outcome |
|---|---|
| Strong relaunch with broad earlier-line label | Material revenue recovery and potential return to a specialty-medicine growth asset |
| Narrow relaunch limited by ocular monitoring | Moderate recovery, with use concentrated in selected treatment centers |
| Positive data but weak reimbursement | Revenue remains below the level needed to justify broad commercial investment |
| Continued regulatory delay | Competitive products capture treatment algorithms and physician preference |
| Biosimilar entry after exclusivity and patent settlement | Price erosion and reduced duration of market exclusivity |
| Strong patent and manufacturing protection | Delayed follow-on entry and greater value from combination indications |
How strong is the BLENREP commercial position?
BLENREP has a credible relaunch case but a fragile market position.
Its strengths are:
- Positive Phase 3 data in earlier treatment settings.
- A differentiated BCMA antibody-drug conjugate mechanism.
- Off-the-shelf availability compared with CAR-T.
- GSK’s global commercial and manufacturing infrastructure.
- Potential use in patients who are not suitable for cellular therapy.
Its weaknesses are:
- A history of failed confirmatory evidence.
- Ocular toxicity requiring specialized monitoring.
- A crowded multiple myeloma market.
- Competition from CAR-T and bispecific therapies with strong response rates.
- The need to rebuild physician confidence after withdrawal.
- Dependence on new regulatory approvals rather than an uninterrupted commercial franchise.
Key Takeaways
- BLENREP’s initial commercial trajectory deteriorated after DREAMM-3 failed and the FDA withdrew its accelerated approval.
- GSK’s historical BLENREP revenue fell to a small specialty-medicine contribution, approximately £60 million in 2023 based on company reporting.
- DREAMM-7 and DREAMM-8 changed the product’s outlook by demonstrating progression-free survival benefits in earlier treatment settings.
- The potential U.S. relaunch is the main value driver.
- Ocular toxicity remains the product’s largest adoption barrier.
- BLENREP competes against CAR-T products, bispecific antibodies, and established anti-CD38 regimens.
- The product faces biosimilar rather than conventional generic risk.
- The 12-year U.S. biologic reference-product exclusivity horizon points to 2032 from the 2020 approval, before accounting for statutory adjustments and patent-specific protection.
- Commercial success will depend on label breadth, reimbursement, treatment sequencing, and the ability to manage eye toxicity without excessive clinical burden.
FAQs
Is BLENREP still available in the United States?
The original U.S. accelerated approval was withdrawn in 2022. Availability depends on a new FDA approval based on the DREAMM-7 and DREAMM-8 development program.
What caused BLENREP sales to decline?
Sales declined because the confirmatory DREAMM-3 trial failed, the U.S. approval was withdrawn, ocular toxicity limited use, and physicians had more competitive BCMA-directed options.
Can BLENREP compete with CAR-T therapy?
Yes, in selected patients. Its principal advantage is off-the-shelf antibody-drug-conjugate treatment without individualized cell manufacturing. CAR-T therapy retains an efficacy and durability advantage for many eligible patients.
Does BLENREP have a conventional Orange Book patent listing?
No conventional small-molecule Orange Book analysis applies to BLENREP in the same manner. It is a biologic and requires analysis of BLA records, biologic exclusivity, patent families, and BPCIA litigation risk.
What would make a BLENREP relaunch commercially successful?
A broad earlier-line label, favorable reimbursement, manageable ophthalmic monitoring, clear positioning before or instead of cellular therapy, and sustained differentiation against bispecific antibodies would be required.
References
- U.S. Food and Drug Administration. (2022). FDA withdraws approval of Blenrep (belantamab mafodotin-blmf) for multiple myeloma.
- GSK plc. (2024). GSK announces positive results from pivotal DREAMM-7 phase III trial for Blenrep in relapsed or refractory multiple myeloma.
- GSK plc. (2024). GSK announces positive results from pivotal DREAMM-8 phase III trial for Blenrep in relapsed or refractory multiple myeloma.
- European Medicines Agency. (2023). Blenrep: European public assessment report and regulatory information.
- GSK plc. (2023). Annual report 2022.
- GSK plc. (2024). Annual report 2023.
- U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, Title VII.
More… ↓
